Paul Sagan bought $1.0M of Moderna (MRNA)
Executed Mar 3 2025, disclosed Mar 4 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Mar 4 2025), the stock returned -8.8% (delay-adjusted); from the execution session (Mar 3 2025), -9.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Paul Sagan (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Moderna, Inc. (MRNA). Across 1 priced purchase filing, the average 21-session return was -9.1% from execution and -8.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of MRNA (31,620 sh × $31.76, as filed), executed Mar 3 2025.
Healthcare · Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→